Peter Kosa, Ph.D.
Peter Kosa joined the MMRF as the Managing Director of the Myeloma Investment Fund (MIF) in March 2019. Dr. Kosa was Senior Director of Business Development at bluebird bio, where he led a business development team which expanded the company’s presence in cellular immunotherapies for multiple myeloma and other cancer and blood diseases through partnerships. Prior to that he was Director of Oncology Strategic Alliances at Novartis Institutes for Biomedical Research, where he had global responsibility for Search and Evaluation of oncology partnerships. He previously worked in business development at XOMA, where he led multiple deals partnering the company’s antibody platform technologies, in business development at Bayer Healthcare where he worked in hemophilia and cardiovascular partnering, and in venture capital at Connecticut Innovations where he served as the Lead Life Science Advisor for venture investments through the nonprofit’s Bioseed and Eli Whitney venture funds. He was a Damon Runyan Cancer Research Postdoctoral Fellow at Harvard Medical School, and earned his B.A. in Biochemistry from Swarthmore College, Ph.D. in Molecular Biophysics from Yale University, and MBA from MIT/Sloan.